Table 1.
Characteristics of patients receiving HSPPC-96 vaccine
| Characteristic | Patients (n = 41) |
|---|---|
| Age, y | |
| Median (range) | 55 (21–75) |
| ≤40 | 3 (7%) |
| 41–50 | 10 (24%) |
| 51–60 | 11 (27%) |
| 61–70 | 15 (37%) |
| >70 | 2 (5%) |
| Gender | |
| Male | 30 (73%) |
| Female | 11 (27%) |
| Ethnicity | |
| White | 39 (95%) |
| Nonwhite | 2 (5%) |
| Karnofsky performance score | |
| 90 | 15 (37%) |
| 80 | 20 (49%) |
| 70 | 6 (14%) |
| Time from diagnosis to progression, wk | |
| Median | 35 |
| Range | 11–321 |
| Time from surgery to first dose of vaccine, days | |
| Median | 31 |
| Range | 23–55 |
| Number of vaccine doses administered | |
| Median | 6 |
| Range | 1–15 |
| Reason for vaccine discontinuation | |
| Progression | 21 (51%) |
| Vaccine depleted | 13 (32%) |
| Patient withdrew | 5 (12%) |
| Investigator decision | 2 (5%) |